Incyte Corporation Stock price

Equities

INCY

US45337C1027

Pharmaceuticals

Real-time Estimate Cboe BZX 01:17:51 2024-03-28 pm EDT 5-day change 1st Jan Change
56.92 USD -0.36% Intraday chart for Incyte Corporation -1.80% -9.73%
Sales 2024 * 4.14B Sales 2025 * 4.61B Capitalization 12.82B
Net income 2024 * 821M Net income 2025 * 1.03B EV / Sales 2024 * 2.02 x
Net cash position 2024 * 4.47B Net cash position 2025 * 5.78B EV / Sales 2025 * 1.53 x
P/E ratio 2024 *
16.3 x
P/E ratio 2025 *
12.7 x
Employees 2,524
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.42%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Incyte Corporation

1 day+1.01%
1 week-1.92%
Current month-2.12%
1 month-6.36%
3 months-8.87%
6 months-3.37%
Current year-9.03%
More quotes
1 week
56.50
Extreme 56.5
57.98
1 month
56.50
Extreme 56.5
61.16
Current year
56.10
Extreme 56.1
67.37
1 year
50.27
Extreme 50.27
76.04
3 years
50.27
Extreme 50.27
88.26
5 years
50.27
Extreme 50.27
110.37
10 years
40.30
Extreme 40.3
153.15
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 14-01-12
Director of Finance/CFO 53 19-02-10
President 60 23-06-04
Members of the board TitleAgeSince
Director/Board Member 57 00-12-31
Director/Board Member 71 19-12-15
Director/Board Member 70 15-01-19
More insiders
Date Price Change Volume
24-03-28 56.71 -0.72% 556 251
24-03-27 57.12 +1.01% 1,653,642
24-03-26 56.55 -1.62% 1,805,731
24-03-25 57.48 +0.88% 1,882,931
24-03-22 56.98 -1.28% 1,192,639

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
57.12 USD
Average target price
76.01 USD
Spread / Average Target
+33.07%
Consensus
  1. Stock
  2. Equities
  3. Stock Incyte Corporation - Nasdaq